A small device implanted just beneath the skin, roughly the size of a large postage stamp and weighing about two grams, kept ...

Gan & Lee Pharmaceuticals (SSE: 603087) today announced that two pivotal phase 3 clinical trials, SUPER-1 and SUPER-2, ...

For over a century, scientists have chased the dream of insulin pills, but the digestive system kept destroying the drug before it could work—forcing millions of patients to rely on daily injections.

“Insulin injections remain a daily burden for many patients,” said Shingo Ito, an associate professor at Kumamoto University ...

The FDA has approved Awiqli, the first once‑weekly long‑acting basal insulin, for adults with type 2 diabetes, which offers ...

On-body injector delivery of subcutaneous teprotumumab achieves clinically meaningful proptosis reduction in phase 3 thyroid eye disease study.

A novel peptide platform from Japan may finally overcome insulin's biggest barrier-surviving digestion – offering hope for a needle-free future.

Mineral casts of cancer cell surfaces reprogram fat cells into stem cells and improve insulin sensitivity in obese mice ...

Amgen announces positive phase 3 results for subcutaneous Tepezza in adults living with moderate-to-severe active thyroid eye disease: Thousand Oaks, California Wednesday, April 8 ...

Drugmakers Novo Nordisk and Eli Lilly and Company have transformed the landscape of chronic weight loss management with the ...

Two Alzheimer's drugs were hailed as treatments that would transform care. Why are barely any UK patients getting them?